Docetaxel based chemotherapy in the treatment of patients with castration resistant prostate cancer

Mangir N., Turkeri L.

ACTAS UROLOGICAS ESPANOLAS, vol.38, no.8, pp.515-522, 2014 (SCI-Expanded) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 38 Issue: 8
  • Publication Date: 2014
  • Doi Number: 10.1016/j.acuro.2013.12.012
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.515-522
  • Keywords: Prostate cancer, Castration resistant, Chemotherapy, Docetaxel, Toxicity, Survival, MITOXANTRONE PLUS PREDNISONE, ELDERLY-PATIENTS, CLINICAL-TRIALS, OLDER, AGE, PARTICIPATION
  • Acibadem Mehmet Ali Aydinlar University Affiliated: Yes


Introduction: Docetaxel administered every 3-weeks is the standart treatment of castration resistant prostate cancer (CRPC) but it is associated with dose limiting toxicities. We analyzed the efficacy and tolerability of 3- weekly and weekly docetaxel in a Turkish cohort of CRPC patients with a special emphasis on the elderly patients.